The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Polycystic Ovary Syndrome (PCOS) is a common cause of female infertility and first line treatment is currently oral clomiphene citrate, a selective estrogen receptor modulator, which results in both a high nonresponse rate and multiple pregnancy rate. Aromatase inhibitors such as letrozole may have more favorable ovarian and endometrial effects. The goal of the Pregnancy in Polycystic Ovary Syndrome II (PPCOSII) study is to determine the safety and efficacy of clomiphene citrate (CC) compared to letrozole, in achieving live birth in infertile women with PCOS. The population will consist of 750 infertile women with PCOS. Additionally, the couple will have no other major infertility factor. This will be a multi-center, prospective, double-blind clinical trial of CC vs. letrozole for 5 treatment cycles (or approximately up to 25 weeks). The randomization scheme will be coordinated through the central data coordinating center (DCC) and the randomization is stratified by each participating site. After progestin withdrawal as needed, 750 women will be equally randomized to two different treatment arms: A) CC 50 mg every day for 5 days (day 3–7 of cycle), or B) letrozole 2.5 mg every day for 5 days (day 3–7 of cycle), for a total of 5 cycles or 25 weeks. The dose will be increased in subsequent cycles in both treatment groups for non-response or poor ovulatory response up to a maximum of 150 mg of CC a day (× 5 days) or 7.5 mg of letrozole a day (× 5 days). The primary analysis will use an intent-to-treat approach to examine differences in the live birth rate in the two treatment arms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Badawy, A., Mosbah, A., & Shady, M. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.05.010 · Cited by 76 · cited 1×
“Further, there were data to suggest that anastrazole and letrozole have varying effectswhen used as ovulation induction agents [45], with letrozole appearing more effective [15].”
BackgroundRetractedRosen, C. B. (2000) · Journal of Sex & Marital Therapy · doi:10.1080/009262300278597 · Cited by 6,593 · cited 2×
“This measure is considered the “gold standard” paper and pencil assessment of sexual function and has excellent psychometric properties (27).”
MethodRosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849 · cited 1×
“The measure addresses the relevant domains of male sexual function (erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction) [28].”
BackgroundPerinatal outcomes in singletons following in vitro fertilization: a meta–analysis
Jackson, R. A., Gibson, K. A., Wu, Y. W., & Croughan, M. S. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000114989.84822.51 · Cited by 1,160
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
Self-citationUltrasound assessment of the polycystic ovary: international consensus definitions
Balen, A. H., Laven, J. S. E., Tan, S.-L., & Dewailly, D. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg044 · Cited by 1,015
Mitwally, M. F. M., & Casper, R. F. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01705-2 · Cited by 800 · cited 2×
“(2001) [14] Open label letrozole only N=12 (PCOS)”
BackgroundVgontzas, A. N., Legro, R. S., Bixler, E. O., Grayev, A., Kales, A., & Chrousos, G. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7185 · Cited by 371
Self-citationMiller, K. K., Rosner, W., Lee, H., Hier, J., Sesmilo, G., Schoenfeld, D., Neubauer, G., & Klibanski, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030680 · Cited by 301 · cited 1×
“The FAI is calculated from measurable values for total T and SHBG, as previously described (18), using the following equation: (FAI = Total testosterone in nmol/L / SHBG in nmol/L) × 100.”
MethodA new era in ovulation induction
Holzer, H., Casper, R., & Tulandi, T. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.05.078 · Cited by 194 · cited 1×
“Aromatase inhibitors (AIs), primarily letrozole, have been promoted as potent ovulation induction agents (10).”
Background
Cited by
Epidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome
Legro, R. S., Brzyski, R. G., Diamond, M. P., Coutifaris, C., Schlaff, W. D., Casson, P., Christman, G. M., Huang, H., Yan, Q., Alvero, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313517 · Cited by 672
Self-citationThe management of patients with polycystic ovary syndrome
Jayasena, C. N., & Franks, S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.102 · Cited by 196
Schisterman, E. F., Sjaarda, L. A., Clemons, T., Carrell, D. T., Perkins, N. J., Johnstone, E., Lamb, D., Chaney, K., Van Voorhis, B. J., Ryan, G., et al. (2020) · JAMA · doi:10.1001/jama.2019.18714 · Cited by 179
Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype
Engmann, L., Jin, S., Sun, F., Legro, R. S., Polotsky, A. J., Hansen, K. R., Coutifaris, C., Diamond, M. P., Eisenberg, E., Zhang, H., et al. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.01.003 · Cited by 144
Self-citationAromatase inhibitors for the treatment of endometriosis
Pavone, M. E., & Bulun, S. E. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.08.053 · Cited by 138
“Because of the increase in FSH and subsequent follicular development that occurs in premenopausal women, treatment with AI must be combined with additional agents to down regulate the ovaries (34, 44, 45).”
BackgroundKuang, H., Li, Y., Wu, X., Hou, L., Wu, T., Liu, J., Ng, E. H. Y., Stener-Victorin, E., Legro, R. S., & Zhang, H. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/527303 · Cited by 67
“Responders are defined as having at least one weekly elevated serum progesterone level indicative of ovulation, that is, >3 ng/mL [43].”
BackgroundSelf-citationContemporary Management of Polycystic Ovarian Syndrome
ZIMMERMAN, L. D., SETTON, R., PEREIRA, N., & ROSENWAKS, Z. (2019) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000449 · Cited by 8
Metadata
- Authors
- Legro, R. S., Kunselman, A. R., Brzyski, R. G., Casson, P. R., Diamond, M. P., Schlaff, W. D., Christman, G. M., Coutifaris, C., Taylor, H. S., Eisenberg, E., Santoro, N., & Zhang, H.
- Venue
- Contemporary Clinical Trials
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 33
- Issue
- 3
- Pages
- 470-481
- ISSN
- 1551-7144 (ISSN-L)
- OpenAlex
- W1994499380
- Cited by
- 65
- References
- 13
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.